Literature DB >> 29769439

CSF1R-dependent myeloid cells are required for NK‑mediated control of metastasis.

Michal Beffinger1, Paulino Tallón de Lara1, Sònia Tugues1, Marijne Vermeer1, Yannick Montagnolo1, Isabel Ohs1, Virginia Cecconi1, Giulia Lucchiari1, Aron Gagliardi1, Nikola Misljencevic1, James Sutton2, Roman Spörri3, Burkhard Becher1, Anurag Gupta1, Maries van den Broek1.   

Abstract

Myeloid leukocytes are essentially involved in both tumor progression and control. We show that neo-adjuvant treatment of mice with an inhibitor of CSF1 receptor (CSF1R), a drug that is used to deplete tumor-associated macrophages, unexpectedly promoted metastasis. CSF1R blockade indirectly diminished the number of NK cells due to a paucity of myeloid cells that provide the survival factor IL-15 to NK cells. Reduction of the number of NK cells resulted in increased seeding of metastatic tumor cells to the lungs but did not impact on progression of established metastases. Supplementation of mice treated with CSF1R-inhibitor with IL-15 restored numbers of NK cells and diminished metastasis. Our data suggest that CSF1R blockade should be combined with administration of IL-15 to reduce the risk of metastasis.

Entities:  

Keywords:  Cancer; Immunology; NK cells; Oncology

Mesh:

Substances:

Year:  2018        PMID: 29769439      PMCID: PMC6012573          DOI: 10.1172/jci.insight.97792

Source DB:  PubMed          Journal:  JCI Insight        ISSN: 2379-3708


  62 in total

1.  Combined IL-15/IL-15Ralpha immunotherapy maximizes IL-15 activity in vivo.

Authors:  Thomas A Stoklasek; Kimberly S Schluns; Leo Lefrançois
Journal:  J Immunol       Date:  2006-11-01       Impact factor: 5.422

2.  Different NK cell developmental events require different levels of IL-15 trans-presentation.

Authors:  Gilbert Aaron Lee; Yae-Huei Liou; Szu-Wen Wang; Kai-Liang Ko; Si-Tse Jiang; Nan-Shih Liao
Journal:  J Immunol       Date:  2011-06-29       Impact factor: 5.422

3.  KLRG1+ NK cells protect T-bet-deficient mice from pulmonary metastatic colorectal carcinoma.

Authors:  Muriel Malaisé; Jordi Rovira; Philipp Renner; Elke Eggenhofer; Manije Sabet-Baktach; Margareta Lantow; Sven A Lang; Gudrun E Koehl; Stefan A Farkas; Martin Loss; Ayman Agha; Josep M Campistol; Hans J Schlitt; Edward K Geissler; Alexander Kroemer
Journal:  J Immunol       Date:  2014-01-10       Impact factor: 5.422

4.  Tumor-associated myeloid cells can be activated in vitro and in vivo to mediate antitumor effects.

Authors:  Alexander L Rakhmilevich; Mark J Baldeshwiler; Tyler J Van De Voort; Mildred A R Felder; Richard K Yang; Nicholas A Kalogriopoulos; David S Koslov; Nico Van Rooijen; Paul M Sondel
Journal:  Cancer Immunol Immunother       Date:  2012-03-06       Impact factor: 6.968

5.  Perforin is a major contributor to NK cell control of tumor metastasis.

Authors:  M J Smyth; K Y Thia; E Cretney; J M Kelly; M B Snook; C A Forbes; A A Scalzo
Journal:  J Immunol       Date:  1999-06-01       Impact factor: 5.422

6.  A cre-transgenic mouse strain for the ubiquitous deletion of loxP-flanked gene segments including deletion in germ cells.

Authors:  F Schwenk; U Baron; K Rajewsky
Journal:  Nucleic Acids Res       Date:  1995-12-25       Impact factor: 16.971

7.  Targeting Suppressive Myeloid Cells Potentiates Checkpoint Inhibitors to Control Spontaneous Neuroblastoma.

Authors:  Yumeng Mao; Nina Eissler; Katarina Le Blanc; John Inge Johnsen; Per Kogner; Rolf Kiessling
Journal:  Clin Cancer Res       Date:  2016-03-08       Impact factor: 12.531

8.  Patrolling monocytes control tumor metastasis to the lung.

Authors:  Richard N Hanna; Caglar Cekic; Duygu Sag; Robert Tacke; Graham D Thomas; Heba Nowyhed; Erica Herrley; Nicole Rasquinha; Sara McArdle; Runpei Wu; Esther Peluso; Daniel Metzger; Hiroshi Ichinose; Iftach Shaked; Grzegorz Chodaczek; Subhra K Biswas; Catherine C Hedrick
Journal:  Science       Date:  2015-10-22       Impact factor: 47.728

9.  IL-15 trans-presentation promotes human NK cell development and differentiation in vivo.

Authors:  Nicholas D Huntington; Nicolas Legrand; Nuno L Alves; Barbara Jaron; Kees Weijer; Ariane Plet; Erwan Corcuff; Erwan Mortier; Yannick Jacques; Hergen Spits; James P Di Santo
Journal:  J Exp Med       Date:  2008-12-22       Impact factor: 14.307

10.  IL-15Ralpha chaperones IL-15 to stable dendritic cell membrane complexes that activate NK cells via trans presentation.

Authors:  Erwan Mortier; Tammy Woo; Rommel Advincula; Sara Gozalo; Averil Ma
Journal:  J Exp Med       Date:  2008-05-05       Impact factor: 14.307

View more
  12 in total

1.  Disruption of CSF-1R signaling inhibits growth of AML with inv(16).

Authors:  Alexander Simonis; Norman F Russkamp; Jan Mueller; C Matthias Wilk; Mattheus H E Wildschut; Renier Myburgh; Nicole Wildner-Verhey van Wijk; Rouven Mueller; Stefan Balabanov; Peter J M Valk; Alexandre P A Theocharides; Markus G Manz
Journal:  Blood Adv       Date:  2021-03-09

2.  Myeloid-Derived Suppressive Cells Promote B cell-Mediated Immunosuppression via Transfer of PD-L1 in Glioblastoma.

Authors:  Catalina Lee-Chang; Aida Rashidi; Jason Miska; Peng Zhang; Katarzyna C Pituch; David Hou; Ting Xiao; Mariafausta Fischietti; Seong Jae Kang; Christina L Appin; Craig Horbinski; Leonidas C Platanias; Aurora Lopez-Rosas; Yu Han; Irina V Balyasnikova; Maciej S Lesniak
Journal:  Cancer Immunol Res       Date:  2019-09-17       Impact factor: 11.151

Review 3.  Macrophages in ovarian cancer and their interactions with monoclonal antibody therapies.

Authors:  Gabriel Osborn; Chara Stavraka; Rebecca Adams; Ahmad Sayasneh; Sharmistha Ghosh; Ana Montes; Katie E Lacy; Rebecca Kristeleit; James Spicer; Debra H Josephs; James N Arnold; Sophia N Karagiannis
Journal:  Clin Exp Immunol       Date:  2022-07-22       Impact factor: 5.732

4.  Cargo-free immunomodulatory nanoparticles combined with anti-PD-1 antibody for treating metastatic breast cancer.

Authors:  Yining Zhang; Kevin R Hughes; Ravi M Raghani; Jeffrey Ma; Sophia Orbach; Jacqueline S Jeruss; Lonnie D Shea
Journal:  Biomaterials       Date:  2021-01-08       Impact factor: 12.479

Review 5.  Monocyte heterogeneity and functions in cancer.

Authors:  Claire E Olingy; Huy Q Dinh; Catherine C Hedrick
Journal:  J Leukoc Biol       Date:  2019-02-18       Impact factor: 4.962

Review 6.  Therapeutic Approaches Targeting the Natural Killer-Myeloid Cell Axis in the Tumor Microenvironment.

Authors:  Larissa S Carnevalli; Hormas Ghadially; Simon T Barry
Journal:  Front Immunol       Date:  2021-04-19       Impact factor: 7.561

7.  MEK1/2 inhibition transiently alters the tumor immune microenvironment to enhance immunotherapy efficacy against head and neck cancer.

Authors:  Manu Prasad; Jonathan Zorea; Sankar Jagadeeshan; Avital B Shnerb; Sooraj Mathukkada; Jebrane Bouaoud; Lucas Michon; Ofra Novoplansky; Mai Badarni; Limor Cohen; Ksenia M Yegodayev; Sapir Tzadok; Barak Rotblat; Libor Brezina; Andreas Mock; Andy Karabajakian; Jérôme Fayette; Idan Cohen; Tomer Cooks; Irit Allon; Orr Dimitstein; Benzion Joshua; Dexin Kong; Elena Voronov; Maurizio Scaltriti; Yaron Carmi; Cristina Conde-Lopez; Jochen Hess; Ina Kurth; Luc G T Morris; Pierre Saintigny; Moshe Elkabets
Journal:  J Immunother Cancer       Date:  2022-03       Impact factor: 12.469

8.  Conventional NK cells and tissue-resident ILC1s join forces to control liver metastasis.

Authors:  Laura Ducimetière; Giulia Lucchiari; Gioana Litscher; Marc Nater; Laura Heeb; Nicolás Gonzalo Nuñez; Laura Wyss; Dominik Burri; Marijne Vermeer; Julia Gschwend; Andreas E Moor; Burkhard Becher; Maries van den Broek; Sonia Tugues
Journal:  Proc Natl Acad Sci U S A       Date:  2021-07-06       Impact factor: 11.205

Review 9.  Immune regulation of metastasis: mechanistic insights and therapeutic opportunities.

Authors:  Olga S Blomberg; Lorenzo Spagnuolo; Karin E de Visser
Journal:  Dis Model Mech       Date:  2018-10-24       Impact factor: 5.758

10.  Emerging roles of IL-34 in health and disease.

Authors:  Iva Lelios; Dilay Cansever; Sebastian G Utz; Wiebke Mildenberger; Sebastian A Stifter; Melanie Greter
Journal:  J Exp Med       Date:  2020-03-02       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.